Pulmonary fibrosis
Conditions
Interventions
Pulmonary fibrosis:None
Control:none
Sponsors
Wuxi People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) IPF patient group: IPF patients must meet the international diagnostic criteria for idiopathic pulmonary fibrosis. The diagnostic criteria include typical manifestations of pulmonary fibrosis shown by imaging examinations (such as high-resolution chest CT), combined with clinical symptoms and pulmonary function assessment, to confirm the evidence of pulmonary fibrosis. All patients voluntarily participate in this study and sign the informed consent form, ensuring they fully understand the purpose, methods, and possible risks of the study during the informed consent process. Patients must agree to provide valid clinical samples (such as blood, lung tissue, etc.) for subsequent biomarker screening, genomic analysis, proteomic research, and other related experiments. These samples will be used for in-depth analysis of potential biomarkers and therapeutic targets related to pulmonary fibrosis and pulmonary arterial hypertension. During the study, participants need to undergo regular clinical evaluations and follow-ups to monitor the progression of the disease and their response to treatment. (2) Control group: This study will recruit control group patients matched in age and gender with the patient group, ensuring they do not have any diseases related to the studied diseases. All patients are lung nodule patients admitted for surgical treatment assessment, with the ability to fully understand the purpose and process of the study and sign the informed consent form, confirming their participation in the study with full knowledge. Blood samples are the excess parts from routine blood draws during hospital admission assessment, and lung tissue is the normal tissue from the distal end of the surgically removed diseased lung, used for biomarker screening and validation experiments in this study. Throughout the process, all data will be strictly confidential to ensure the privacy of the subjects is fully protected.
Exclusion criteria
Exclusion criteria: (1) IPF patient group: The exclusion criteria for this group include patients with severe heart diseases, diabetes, liver and kidney dysfunction, or other systemic diseases, as these conditions may be related to pulmonary fibrosis and could affect the analysis of the research results. Pregnant or lactating women were also excluded to avoid unnecessary risks associated with the study. Patients with a recent history of major surgery or severe infection would not be included in the study as these health conditions could lead to significant changes in clinical status and affect the stability of experimental data. If patients have concurrent malignant tumors, immune system diseases, or any other conditions that may affect the research results, they do not meet the research criteria. Finally, patients who cannot provide sufficient biological samples (such as blood, lung tissue, etc.) for further analysis will also be excluded. (2) Control group: The exclusion criteria for this group include any diseases related to the studied disease, as these diseases may affect the screening of biomarkers and the analysis results. Pregnant or lactating women will be excluded to ensure that there are no potential risks to the health of the mother and the fetus in the study. Patients with a recent history of major surgery or severe infection do not meet the inclusion criteria as these factors may affect the physiological state and the reliability of the experimental results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mettl1; | — |
Secondary
| Measure | Time frame |
|---|---|
| Echocardiogram;Lung function; | — |
Countries
China
Contacts
Public ContactJialong Liang
Wuxi People's Hospital
Outcome results
None listed